Loading…
Alpha Tau Medical Ltd. is projected to rise to $15.84 by 2027, a +25% move from its current price of $12.71. DRTS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $12.19 | $12.70 | $13.24 | -0.05% |
| Jul 14 | $11.98 | $12.70 | $13.46 | -0.09% |
| Jul 15 | $11.82 | $12.69 | $13.63 | -0.14% |
| Jul 16 | $11.69 | $12.69 | $13.77 | -0.19% |
| Jul 17 | $11.57 | $12.68 | $13.90 | -0.23% |
| Jul 18 | $11.46 | $12.67 | $14.02 | -0.28% |
| Jul 19 | $11.36 | $12.67 | $14.12 | -0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.36 | $12.67 | $14.12 | -0.33% |
| Week 2 | $10.83 | $12.63 | $14.73 | -0.65% |
| Week 3 | $10.43 | $12.59 | $15.19 | -0.98% |
| Week 4 | $10.09 | $12.54 | $15.59 | -1.30% |
| Week 5 | $9.80 | $12.50 | $15.95 | -1.62% |
| Week 6 | $9.55 | $12.46 | $16.27 | -1.94% |
| Week 7 | $9.32 | $12.42 | $16.56 | -2.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Alpha Tau Medical operates within the Healthcare category and trades under the ticker symbol DRTS.}
Alpha Tau Medical Ltd. (DRTS) is currently priced at $13.58 with a market capitalization of $1.23B. It ranks 2397 in market listings, reflecting its position among peers.
The price outlook shown by the year-by-year forecast indicates rising averages beyond 2026, with 2026 expected to have an average of $13.58 and a range from $4.83 to $18.40. The forecast grows through 2027–2035, reaching a 2030 average of $29.81 and a 2040 average of $85.63, before projecting a 2050 average of $175.75.
Longer-horizon targets show strong upside, with 2030 ROI of 119.6 and 2050 ROI of 1194.7, and a bullish sentiment continuing through 2031–2050. This suggests meaningful upside potential relative to the current price, albeit with uncertainty inherent in any forecast.}
A major floor 49.6% below — a decisive break under it would weaken the trend.
The nearest floor, 29.7% below — buyers have tended to step in here.
The nearest ceiling, 6.8% above — a clean break opens room to run.
A major ceiling 28.9% above — clearing it would confirm fresh momentum.
Key DRTS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DRTS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.96 | Sell | $12.78 | Sell |
| MA 10 | $12.53 | Buy | $12.39 | Buy |
| MA 20 | $11.22 | Buy | $11.64 | Buy |
| MA 50 | $10.18 | Buy | $10.37 | Buy |
| MA 100 | $8.77 | Buy | $9.10 | Buy |
| MA 200 | $6.90 | Buy | $7.50 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.55 | Neutral |
| Stoch RSI (14) | 50.92 | Neutral |
| CCI (20) | 73.64 | Neutral |
| Williams %R (14) | -22.91 | Info |
| MACD (12,26,9) | 0.15 | Buy |
| ROC (12) | 29.69 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 77.09 | Neutral |
| TRIX (15) | 1.04 | Buy |
| Awesome (5,34) | 2.27 | Buy |
| Ultimate (7,14,28) | 59.47 | Neutral |
| Momentum (10) | 1.54 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 12.93 | Sell |
| ADX (14) | 23.51 | Buy |
| ATR (14) | 0.41 | Info |
30-day technical picture:
- 30-day range: $10.15 to $18.15, indicating a broad trading band. - Current price sits near the upper end of that band, at $13.58, with a nearby resistance at $13.57.
Momentum indicators show bullish tone: RSI(14) is 70, and overall sentiment is BULLISH. The 50-day simple moving average is $9.78, well above the 200-day simple moving average of $6.72, suggesting upward momentum in the near term.
Support sits at $8.93, with resistance at $13.57, defining a tight set of near-term thresholds for price action.}
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.83 | $12.71 | $17.18 | 0% | Neutral | |
| $12.02 | $15.84 | $22.41 | +25% | Bullish | |
| $12.95 | $17.85 | $26.58 | +40% | Bullish | |
| $12.90 | $18.45 | $28.60 | +45% | Bullish | |
| $19.12 | $28.27 | $45.32 | +122% | Bullish | |
| $23.69 | $36.14 | $59.63 | +184% | Bullish | |
| $23.85 | $37.45 | $63.41 | +195% | Bullish | |
| $27.19 | $43.89 | $76.05 | +245% | Bullish | |
| $27.38 | $45.40 | $80.34 | +257% | Bullish | |
| $27.60 | $46.95 | $84.73 | +269% | Bullish | |
| $46.00 | $88.24 | $172.68 | +594% | Bullish | |
| $80.47 | $178.83 | $392.76 | +13.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.83 | $12.71 | $15.38 | +0.00% |
| August 2026 | $10.20 | $12.21 | $15.11 | -3.95% |
| September 2026 | $10.07 | $12.18 | $15.33 | -0.23% |
| October 2026 | $10.61 | $12.95 | $16.53 | +6.35% |
| November 2026 | $10.78 | $13.26 | $17.11 | +2.38% |
| December 2026 | $10.63 | $13.17 | $17.18 | -0.66% |
Click any year to see its month-by-month DRTS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, DRTS could reach as high as $17.18, with a base case around $12.71 and support toward $4.83 — roughly 0% from $12.71. Price action looks broadly range-bound.
Expect DRTS to range from $12.02 to $22.41 through 2027. The $15.84 average target implies a +25% move from current prices. That is up +25% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The DRTS price prediction for 2028 points to an average of $17.85 (low $12.95, high $26.58) — a potential gain of +40% on today's $12.71. Momentum favours further upside here.
In 2029, DRTS is projected to trade between $12.90 and $28.60, averaging $18.45 — a potential gain of +45% from today's $12.71. That is up +3% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Alpha Tau Medical Ltd.'s 2030 outlook centres on $28.27, within a $19.12 to $45.32 range. That is up +53% on the projected 2029 average. That marks a +122% change versus current levels. Momentum favours further upside here.
By 2031, DRTS could reach as high as $59.63, with a base case around $36.14 and support toward $23.69 — roughly +184% from $12.71. Buyers look set to stay in control over this stretch.
Expect DRTS to range from $23.85 to $63.41 through 2032. The $37.45 average target implies a +195% move from current prices. That is up +4% on the projected 2031 average. Momentum favours further upside here.
The DRTS price prediction for 2033 points to an average of $43.89 (low $27.19, high $76.05) — a potential gain of +245% on today's $12.71. Buyers look set to stay in control over this stretch.
In 2034, DRTS is projected to trade between $27.38 and $80.34, averaging $45.40 — a potential gain of +257% from today's $12.71. That is up +3% on the projected 2033 average. Momentum favours further upside here.
Alpha Tau Medical Ltd.'s 2035 outlook centres on $46.95, within a $27.60 to $84.73 range. That is up +3% on the projected 2034 average. That marks a +269% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, DRTS could reach as high as $172.68, with a base case around $88.24 and support toward $46.00 — roughly +594% from $12.71. Momentum favours further upside here.
Expect DRTS to range from $80.47 to $392.76 through 2050. The $178.83 average target implies a +13.1x move from current prices. That is up +103% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in DRTS today (≈ 78.678206 DRTS) could be worth
$14,070.15
+$13,070.15 (+1307%) by 2050 · US Dollar
Based on the average projected DRTS price of $178.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DRTSwould be worth at today's price.
$1,000 invested in DRTS on Jul 10, 2025 (≈ 317.460308 DRTS) would be worth
$4,034.92
+$3,034.92 (+303.5%) today · 4.03× · US Dollar
Based on a DRTS entry price of $3.15 vs. today's $12.71.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.23 | $960.7 | -3.9% |
| 1 month ago | $9.24 | $1,375.54 | +37.6% |
| 3 months ago | $7.29 | $1,743.48 | +74.3% |
| 6 months ago | $7.09 | $1,792.67 | +79.3% |
| 1 year ago | $3.15 | $4,034.92 | +303.5% |
| All time (5.0y) ago | $9.79 | $1,298.26 | +29.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DRTS forecast.
Our base-case forecast reaches $25.00 around 2030.
Implied market cap at $25.00: $2.26B
The multi-year forecast paints a clear longer-horizon path of upside for Alpha Tau Medical Ltd. By 2026 the average forecast is $13.58 with a minimum of $4.83 and a maximum of $18.40, indicating little deviation from the current level in the near term.
From 2027 onward the averages rise steadily, with 2027 at $16.66 and 2028 at $18.34, then climbing to 2030 at $29.81 and continuing to 2040 at $85.63. The 2050 forecast reaches $175.75 on average, with a maximum of $399.31, underscoring substantial long-term upside.
ROI figures accompany the path: 2030 ROI 119.6, 2040 ROI 530.8, and 2050 ROI 1194.7, alongside a bullish sentiment for most of the horizon. Drivers and risks are inherent in any long-term projection, and these figures are estimates rather than guarantees.}
Tap a question to reveal the answer.
In 2030 the forecast shows min $19.73, avg $29.81, max $48.77 with ROI 119.6 and a bullish sentiment.
The forecast indicates bullish sentiment from 2027 onward with rising averages: 2027 avg $16.66, 2030 avg $29.81, 2040 avg $85.63, 2050 avg $175.75. ROI grows to 119.6 by 2030 and to 1194.7 by 2050, though 2026 is neutral at avg $13.58 and ROI 0.
Yes. The 2040 forecast includes a max of $172.57, and the 2050 max is $399.31, indicating a path that could exceed $100 by 2040.
Current price is $13.58 and market cap is $1.23B.
The 30-day range is $10.15 to $18.15.
Alpha Tau Medical Ltd. Community Discussion
0Share your Alpha Tau Medical Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.